EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Multicenter randomized phase II study of docetaxel given q3w vs q1w plus trastuzumab as first line therapy for HER2 overexpressing adjuvant anthracyclin pretreated metastatic breast cancer



Multicenter randomized phase II study of docetaxel given q3w vs q1w plus trastuzumab as first line therapy for HER2 overexpressing adjuvant anthracyclin pretreated metastatic breast cancer



Breast Cancer Research & Treatment 76(Supplement 1): S114, December




(PDF 0-2 workdays service: $29.90)

Accession: 035349907

Download citation: RISBibTeXText



Related references

Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer. Breast Cancer Research and Treatment 95(1): 45-53, 2005

Multicenter, phase II, nonrandomized study of docetaxel plus trastuzumab every 21 days as the primary therapy in metastatic breast cancer overexpressing HER2. Anti-Cancer Drugs 23(2): 239-246, 2012

Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. Journal of Clinical Oncology 29(2): 149-156, 2011

Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast cancer: HERTAX trial. Clinical Breast Cancer 11(2): 103-113, 2011

A prospective multicenter phase II study of oral and i.v. vinorelbine plus trastuzumab as first-line therapy in HER2-overexpressing metastatic breast cancer. Annals of Oncology 22(3): 603-608, 2011

Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II and pharmacokinetic study in Japan. Anti-Cancer Drugs 19(7): 753-759, 2008

Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial. Annals of Oncology 17(3): 409-414, 2005

Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group. Breast Cancer Research and Treatment 119(1): 127-136, 2010

Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer. Breast Cancer Research 16(3): R50-R50, 2015

Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. Journal of Clinical Oncology 28(6): 976-983, 2010

Combined trastuzumab (HER)/docetaxel (TAX) versus sequential trastuzumab followed by docetaxel at progression as first line chemotherapy for Her2-positive metastatic breast cancer: preliminary results (multicenter BOOG-study; 2002-02). 2007

Patterns of Care and Clinical Outcomes of First-Line Trastuzumab-Based Therapy in HER2-Positive Metastatic Breast Cancer Patients Relapsing After (Neo)Adjuvant Trastuzumab: An Italian Multicenter Retrospective Cohort Study. Oncologist 20(8): 880-889, 2016

Phase II Study of Vinorelbine Plus Trastuzumab in HER2 Overexpressing Metastatic Breast Cancer Pretreated with Anthracyclines and Taxanes. Journal of Breast Cancer 14(2): 140-146, 2011

AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. Journal of Clinical Oncology 31(14): 1719-1725, 2013

Safety and activity of docetaxel and trastuzumab in HER2 overexpressing metastatic breast cancer: a pilot phase II study. American Journal of Clinical Oncology 26(1): 95-97, 2003